Since no LL cell lines are available, formal experimental support could not be provided; however, the potential role of PI3K/Akt/mTOR inhibitors is under investigation in other PTCL subtypes (Martín-Sánchez et al., 2013; Horwitz et al., 2018). The gene discussed is AKT1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.